Skip to content

Study · Not a test of the peptide alone · 2026

16 results

Sustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.

Yovera-Aldana M, Manrique-Hurtado H, Umpierrez GE

JCEM case reports16 Sept 2026

PMID42751099 (opens in a new tab)DOI10.1210/jcemcr/luag260 (opens in a new tab)PepBankPUB-42751099
Publisher pagePubMedAsk about this study
Jump to 16 results

Summary

Prader-Willi syndrome (PWS) is a neurogenetic disorder characterized by hyperphagia, severe obesity, and early-onset metabolic complications, in which durable weight loss is rarely achieved. We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]). He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise. At 18 months, total weight loss reached 58.8% (-108.7 kg), with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications. Mild transient gastrointestinal symptoms occurred during dose escalation, with no serious adverse events. Follow-up bioimpedance showed a skeletal muscle mass of 38.5 kg after a 58.8% reduction in total body weight.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study16

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone16

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 01HumanNot a test of Retatrutide aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, sequential incretin therapy starting with retatrutide led to total weight loss of 58.8% (-108.7 kg) at 18 months.

    In plain wordsA man with Prader-Willi syndrome lost a large share of his weight on sequential incretin drugs that began with retatrutide, with diet and exercise.

    Peptide
    Retatrutide
    Outcome
    DecreaseTotal weight loss at 18 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Total weight loss
    58.8%
    18 months
    Weight change
    −108.7 kg
    18 months

    Source sentences

    Summary
    At 18 months, total weight loss reached 58.8% (-108.7 kg)
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.

  2. 02HumanNot a test of Retatrutide aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome and type 2 diabetes, HbA1c reached 4.9%, consistent with diabetes remission off all glucose-lowering medications, after sequential therapy starting with retatrutide.

    In plain wordsA man with Prader-Willi syndrome and type 2 diabetes reached diabetes remission after sequential incretin drugs that began with retatrutide, with diet and exercise.

    Peptide
    Retatrutide
    Outcome
    DecreaseHbA1c and diabetes remission
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    4.9%
    18 months

    Source sentences

    Summary
    with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.

  3. 03HumanNot a test of Retatrutide aloneCase report or seriesSafety outcome

    In a man with Prader-Willi syndrome given sequential incretin therapy starting with retatrutide, mild transient gastrointestinal symptoms occurred during dose escalation.

    In plain wordsA man with Prader-Willi syndrome on sequential incretin drugs had mild, short gastrointestinal symptoms while the dose was raised.

    Peptide
    Retatrutide
    Outcome
    IncreaseGastrointestinal symptoms during dose escalation
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Mild transient gastrointestinal symptoms occurred during dose escalation, with no serious adverse events.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.

  4. 04HumanNot a test of Retatrutide aloneCase report or seriesSafety outcome

    In a man with Prader-Willi syndrome given sequential incretin therapy starting with retatrutide, no serious adverse events occurred.

    In plain wordsA man with Prader-Willi syndrome on sequential incretin drugs had no serious adverse events.

    Peptide
    Retatrutide
    Outcome
    No significant changeSerious adverse events
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    with no serious adverse events.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.

  5. 05HumanNot a test of Retatrutide aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, bioimpedance showed a skeletal muscle mass of 38.5 kg after a 58.8% reduction in total body weight.

    In plain wordsA man with Prader-Willi syndrome had a skeletal muscle mass of 38.5 kg after large weight loss on sequential incretin drugs, diet and exercise.

    Peptide
    Retatrutide
    Outcome
    Not applicableSkeletal muscle mass after weight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Skeletal muscle mass
    38.5 kg
    follow-up bioimpedance

    Source sentences

    Summary
    Follow-up bioimpedance showed a skeletal muscle mass of 38.5 kg after a 58.8% reduction in total body weight.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Retatrutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Retatrutide.

  6. 06HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, sequential incretin-based therapy (retatrutide, then oral semaglutide, then dulaglutide) with diet and exercise gave 58.8% total weight loss at 18 months.

    In plain wordsIn one man with Prader-Willi syndrome, a sequence of three incretin drugs with diet and exercise was followed by 58.8% weight loss.

    Peptide
    Semaglutide
    Outcome
    DecreaseTotal weight loss at 18 months
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    total weight loss
    58.8%
    18 months
    weight change
    −108.7 kg
    18 months

    Source sentences

    Summary
    At 18 months, total weight loss reached 58.8% (-108.7 kg), with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  7. 07HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome and type 2 diabetes, sequential incretin-based therapy was followed by HbA1c of 4.9%, consistent with diabetes remission off glucose-lowering medication.

    In plain wordsIn one man with Prader-Willi syndrome and diabetes, HbA1c reached 4.9% after a sequence of three incretin drugs, with diabetes remission.

    Peptide
    Semaglutide
    Outcome
    DecreaseHbA1c at 18 months
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    4.9%
    18 months

    Source sentences

    Summary
    At 18 months, total weight loss reached 58.8% (-108.7 kg), with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  8. 08HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In a man with Prader-Willi syndrome, mild transient gastrointestinal symptoms occurred during dose escalation of sequential incretin-based therapy.

    In plain wordsIn one man with Prader-Willi syndrome, mild short-lived stomach and gut symptoms occurred while doses were raised.

    Peptide
    Semaglutide
    Outcome
    Not applicableGastrointestinal symptoms
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Mild transient gastrointestinal symptoms occurred during dose escalation
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  9. 09HumanNot a test of Semaglutide aloneCase report or seriesSafety outcome

    In a man with Prader-Willi syndrome, sequential incretin-based therapy was associated with no serious adverse events.

    In plain wordsIn one man with Prader-Willi syndrome, a sequence of three incretin drugs caused no serious adverse events.

    Peptide
    Semaglutide
    Outcome
    No significant changeSerious adverse events
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    no serious adverse events.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  10. 10HumanNot a test of Semaglutide aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, skeletal muscle mass was 38.5 kg after a 58.8% reduction in total body weight on sequential incretin-based therapy.

    In plain wordsIn one man with Prader-Willi syndrome, skeletal muscle mass measured 38.5 kg after 58.8% weight loss on a sequence of incretin drugs.

    Peptide
    Semaglutide
    Outcome
    Not applicableSkeletal muscle mass after weight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    skeletal muscle mass
    38.5 kg
    follow-up

    Source sentences

    Summary
    Follow-up bioimpedance showed a skeletal muscle mass of 38.5 kg after a 58.8% reduction in total body weight.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

  11. 11HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, sequential incretin therapy with diet and exercise accompanied 58.8% weight loss at 18 months.

    In plain wordsIn a man with Prader-Willi syndrome, sequential drug therapy with diet and exercise accompanied substantial weight loss.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseWeight loss
    Study

    n = 1

    Outcome group
    Body weight · Metabolic and weight

    Measurements

    Weight loss
    58.8%
    18 months
    Weight change
    −108.7 kg
    18 months

    Source sentences

    Summary
    At 18 months, total weight loss reached 58.8% (-108.7 kg), with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  12. 12HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, HbA1c reached 4.9% after sequential incretin therapy with diet and exercise.

    In plain wordsIn a man with Prader-Willi syndrome, blood sugar improved after sequential drug therapy with diet and exercise.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Measurements

    HbA1c
    8.3%
    baseline
    HbA1c
    67 mmol/mol
    baseline
    HbA1c
    4.9%
    18 months
    HbA1c
    30 mmol/mol
    18 months

    Source sentences

    Summary
    At 18 months, total weight loss reached 58.8% (-108.7 kg), with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  13. 13HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, sequential incretin therapy with diet and exercise preceded diabetes remission after all glucose-lowering medications stopped.

    In plain wordsIn a man with Prader-Willi syndrome, diabetes remission followed sequential drug therapy with diet and exercise, after diabetes medicines stopped.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableDiabetes remission
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    At 18 months, total weight loss reached 58.8% (-108.7 kg), with HbA1c of 4.9% (SI: 30 mmol/mol), consistent with diabetes remission after discontinuation of all glucose-lowering medications.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  14. 14HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome

    In a man with Prader-Willi syndrome receiving sequential incretin therapy, mild transient gastrointestinal symptoms occurred during dose escalation.

    In plain wordsIn a man with Prader-Willi syndrome, mild temporary digestive symptoms occurred during dose increases in sequential drug therapy.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableGastrointestinal symptoms
    Study

    n = 1

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    Mild transient gastrointestinal symptoms occurred during dose escalation, with no serious adverse events.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  15. 15HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesSafety outcome

    In a man with Prader-Willi syndrome receiving sequential incretin therapy, no serious adverse events occurred.

    In plain wordsIn a man with Prader-Willi syndrome, sequential drug therapy involved no serious adverse events.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableSerious adverse events
    Study

    n = 1

    Outcome group
    Adverse events · Whole body

    Source sentences

    Summary
    Mild transient gastrointestinal symptoms occurred during dose escalation, with no serious adverse events.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

  16. 16HumanNot a test of Dulaglutide (Trulicity) aloneCase report or seriesEfficacy outcome

    In a man with Prader-Willi syndrome, skeletal muscle mass measured 38.5 kg after weight loss during sequential incretin therapy.

    In plain wordsIn a man with Prader-Willi syndrome, muscle mass measured 38.5 kg after weight loss during sequential drug therapy.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    Not applicableSkeletal muscle mass
    Study

    n = 1

    Outcome group
    Body composition · Musculoskeletal

    Measurements

    Skeletal muscle mass
    38.5 kg
    follow-up bioimpedance

    Source sentences

    Summary
    Follow-up bioimpedance showed a skeletal muscle mass of 38.5 kg after a 58.8% reduction in total body weight.
    2 context sentences
    Summary · context
    We report a 29-year-old man with genetically confirmed maternal uniparental disomy PWS who presented with severe obesity (185 kg; body mass index [BMI] 59.7 kg/m2) and newly diagnosed type 2 diabetes (glycated hemoglobin [HbA1c], 8.3% [SI: 67 mmol/mol] [reference range, <5.7% (SI: <39 mmol/mol)]).
    Summary · context
    He received sequential incretin-based therapy, initiated with retatrutide (1-12 mg weekly) within a clinical trial, followed by oral semaglutide and then dulaglutide after retatrutide became unavailable, together with a structured hypocaloric diet and supervised exercise.

    In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 34 to 42Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 9 times, first on 22 Oct 2026, 02:25 UTC. The status did not change between them.

    Study results updated

  2. Version 33

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Versions 3 to 32

    21 Oct 2026, 17:06 UTC

    The same notice was added 30 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  4. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  5. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.